Posted by Michael Wonder on 31 Jan 2019
Vertex an “extreme outlier” in pricing and behaviour, says NHS England
31 January 2019 - Members of parliament aim to break three year deadlock.
A very public row about the price of Vertex’s cystic fibrosis drug Orkambi between the company and NHS England has been reignited ahead of a parliamentary inquiry.
The drug is a breakthrough life-extending treatment for the genetically inherited lung condition, but patients in England are still unable to access it on the NHS because of the pricing row, which has rumbled on since 2016.
